Objective To determine the expression profile of FERMT1 in gliomas， and to explore the clinical significance and its biological processes involved in the development and progression of gliomas. Methods Clinical data and RNA sequencing expression data from 309 glioma patients was obtained from the Chinese Glioma Genome Atlas（ CGGA） database. According to FERMT1 expression， they were divided into high expression group and low expression group， and the expression characteristics were analyzed. While 609 samples from the Cancer Genome Atlas（ TCGA） mRNA sequencing database were used as controls to verify the expression characteristics of FERMT1 in glioma patients. Kaplan Meier method， Log-rank test and Cox regression model were used to evaluate the relationship between FERMT1 expression and the survival of glioma patients. Gene oncology（ GO） and Kyoto Encyclopedia of Genes and Genomes（ KEGG） were performed for the functional analysis of FERMT1. Results In the CGGA（ 309 cases） and TCGA datasets（ 609 cases）， the expression of FERMT1 was distinct from WHO Ⅱ， Ⅲ and Ⅳ grade with statistical significance（ F=30.08， 91.72， respectively， P＜ 0.01）， with the lowest expression in WHO Ⅱ grade and the highest in WHO Ⅳ grade. FERMT1 expression is higher in isocitrate dehydrogenase（ IDH） mutant gliomas（ t=19.87，30.72， respectively， P＜0.01）. The receiver operating characteristic（ ROC） curve showed that FERMT1 expression could well predict IDH mutant gliomas， and the area under the curve（ AUC） were 92.7% and 94.8%， respectively. In the two cohorts， there were significant differences in FERMT1 expression in different subtypes（ F=94.04，300.20， P ＜ 0.01）， with the highest expression level in proneural subtype. The expression of FERMT1 was higher in the methylation group of O6 methylguanine methyltransferase（ MGMT） promoter， and the difference was statistically significant（ t=6.65，13.41， respectively， P＜0.01）. The patients with high expression of FERMT1 had dramatically shorter overall survival than low-expression counterparts in CGGA and TCGA RNAseq databases（ P＜0.01）. The results of single factor and multivariate Cox regression analysis showed that FERMT1 expression and pathological grade were independent risk factors influencing prognosis of glioblastoma patients （RR=0.718， 95%CI：0.517-0.996，P=0.047；RR=2.519， 95%CI： 1.763-3.599，P ＜ 0.001）. GO enrichment analysis showed that the genes negative related with FERMT1 expression were enriched in "cell-cell adhesion"， "extracellular matrix organization"， "inflammatory response"， "Leukocyte migration"， "chemotaxis" and other biological process. KEGG pathway enrichment analysis showed that genes negative related with FERMT1 were enriched in "cytoskeletal regulation"， "focal adhesion"， "ECM-receptor interaction" and other pathways. Conclusions FERMT1 can be used as a potential indicator to predict the prognosis of glioma patients， and might provide a new perspective for the research and individual therapy of glioma.